Life Science Daily News: The Evidence Gap in Precision Prevention

Written by: Dr. Nicki Byrne, Clinical Director

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a decade ago. This shift has fueled the rise of precision prevention: tailoring preventive strategies to an individual’s unique biological profile rather than relying solely on population-level recommendations. 

Yet as precision prevention advances, a critical challenge remains: the evidence frameworks we use to evaluate medical interventions have not evolved at the same pace.

Across medicine, clinical decision-making has traditionally been guided by evidence hierarchies that place randomized controlled trials (RCTs) at the top. RCTs remain the gold standard for establishing causality and have transformed modern healthcare. However, many of the tools and interventions emerging within precision prevention do not fit neatly within traditional evidence-generation models. As a result, clinicians, researchers, regulators, and patients are increasingly confronted with an important question: How should we evaluate potentially valuable signals when definitive RCT evidence does not yet exist?

The answer is unlikely to be found in abandoning evidence-based medicine. Rather, it requires expanding our understanding of what constitutes actionable evidence in the context of prevention.

To continue reading the full article, Click Here